OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press91410.17650/1818-8346-2024-19-2-118-131SUPPORTIVE THERAPY ASPECTSАСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИImportant aspects of carbohydrate metabolism disorders development in hematology/oncology patients during therapy with glucocorticosteroids: a review of the literatureВажные аспекты развития нарушения углеводного обмена у онкогематологических больных на фоне терапии глюкокортикостероидами: обзор литературыhttps://orcid.org/0000-0003-4307-1522VatutinN. T.ВатутинН. Т.
Russian Federation

16 Prospekt Ilyicha, Donetsk 283003, Donetsk People’s Republic; 47 Prospekt Leninskiy, Donetsk 283045, Donetsk People’s Republic

Донецкая народная республика, 283003 Донецк, пр-кт Ильича, 16; Донецкая народная республика, 283045 Донецк, пр-кт Ленинский, 47

https://orcid.org/0000-0002-0656-7097SklyannayaE. V.СкляннаяЕ. В.
Russian Federation

16 Prospekt Ilyicha, Donetsk 283003, Donetsk People’s Republic; 47 Prospekt Leninskiy, Donetsk 283045, Donetsk People’s Republic

Донецкая народная республика, 283003 Донецк, пр-кт Ильича, 16; Донецкая народная республика, 283045 Донецк, пр-кт Ленинский, 47

https://orcid.org/0009-0001-2668-1102GribovV. V.ГрибовВ. В.
Russian Federation

Vadim V. Gribov.

16 Prospekt Ilyicha, Donetsk 283003, Donetsk People’s Republic; 12 Ferganskaya St., Makeevka 286120, Donetsk People’s Republic

Грибов Вадим Валентинович.

Донецкая народная республика, 283003 Донецк, пр-кт Ильича, 16; Донецкая народная республика, 286120 Макеевка, ул. Ферганская, 12

gribov_vv@bk.ruDonetsk State Medical University named after M. Gorky, Ministry of Health of RussiaФГБОУ ВО «Донецкий государственный медицинский университет им. М. Горького» Минздрава РоссииV.K. Gusak Institute of Emergency and Reconstructive Surgery, Ministry of Health of RussiaФГБУ «Институт неотложной и восстановительной хирургии им. В.К. Гусака» Минздрава РоссииCity Hospital No. 2 of MakeevkaГородская больница № 2 г. Макеевки030420241921181311001202402042024https://oncohematology.abvpress.ru/ongm/article/view/914

Glucocorticosteroids are highly effective anti-inflammatory and immunosuppressive agents. The drugs were introduced into therapeutic practice from the mid-20th century and are still widely used in the treatment of various diseases. They are an integral part of the treatment of patients with hematological malignancies. One of the clinically significant complications of glucocorticosteroid therapy is steroid-induced carbohydrate metabolism disorders. Diabetes mellitus is one of the main risk factors for the development of cardiovascular diseases, which are the main non-oncological cause of death in the population and a significant treatment complication in patients with malignant neoplasms. Early detection of the disease and improved treatment efficiency increase the survival rate of patients with various types of neoplasms. It is also important to pay attention to quality of life improving in cancer patients after treatment.

The aim of this review is to analyze the pathogenesis features, as well as predictors of early detection and prevention of possible complications of persistent hyperglycemia in patients with hematological malignancies.

Глюкокортикостероиды – высокоэффективные противовоспалительные и иммуносупрессивные средства. В терапевтическую практику препараты были внедрены с середины XX века и до настоящего времени широко используются в лечении различных заболеваний. Они являются неотъемлемой частью терапии пациентов с онкогематологическими заболеваниями. Одно из клинически значимых осложнений терапии глюкокортикостероидами – стероидиндуцированное нарушение метаболизма углеводов. Сахарный диабет – один из основных факторов риска развития кардиоваскулярных заболеваний, которые являются основной неонкологической причиной смерти населения и существенным осложнением терапии лиц со злокачественными новообразованиями. Раннее выявление заболевания и улучшение эффективности лечения повышают выживаемость пациентов с новообразованиями различных типов. Также важно уделять внимание повышению качества жизни онкологических больных после проведенного лечения.

Цель данного обзора – анализ особенностей патогенеза развития, а также предикторов раннего выявления и предупреждения развития возможных осложнений персистенции гипергликемии у онкогематологических больных.

glucocorticosteroidsteroid-induced carbohydrate metabolism disordersteroid-induced hyperglycemiasteroid-induced diabetes mellitusrisk factorглюкокортикостероидстероидиндуцированное нарушение углеводного обменастероидиндуцированная гипергликемиястероидиндуцированный сахарный диабетфактор рискаMalignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.Healy S.J., Nagaraja H.N., Alwan D., Dungan K.M. Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies. Endocrine 2017;56(1):90–7. DOI: 10.1007/s12020-016-1220-2Harris D., Barts A., Connors J. et al. Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study. Curr Oncol 2013;20(6):e532–8. DOI: 10.3747/co.20.1499Hwangbo Y., Kang D., Kang M. et al. Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol 2018;4(8):1099–105. DOI: 10.1001/jamaoncol.2018.1684Toyoshima M.T.K., Cukier P., Souza A.B.C. et al. Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study. Einstein (Sao Paulo) 2022;20:eAO8031. DOI: 10.31744/einstein_journal/2022AO8031Hiestand A., Flory J., Chitkara R. Hospitalization as an opportunity to optimize glycemic control in oncology patients. Curr Diab Rep 2019;19(12):149. DOI: 10.1007/s11892-019-1283-6Wu L., Jiao Y., Li Y. et al. Hepatic Gadd45β promotes hyperglycemia and glucose intolerance through DNA demethylation of PGC-1α. J Exp Med 2021;218(5):e20201475. DOI: 10.1084/jem.20201475Dehghani M., Hobbi A.M., Haghighat S. et al. Glucocorticoid induced diabetes and lipid profiles disorders amongst lymphoid malignancy survivors. Diabetes Metab Syndr 2020;14(6):1645–9. DOI: 10.1016/j.dsx.2020.08.027Chang K.H., Hwang W.L., Muo C.H. et al. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study. Support Care Cancer 2016;24(12): 4993–5000. DOI: 10.1007/s00520-016-3361-5Vidler J., Rogers C., Yallop D. et al. Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids. J Clin Transl Endocrinol 2017;9: 18–20. DOI: 10.1016/j.jcte.2017.06.003Ochola L.A., Nyamu D.G., Guantai E.M., Weru I.W. Metformin’s effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers. J Oncol Pharm Pract 2020;26(4):823–34. DOI: 10.1177/1078155219873048Selimov A.Yu., Eliseeva L.N., Kurinnaya V.P., Oranskii S.P. Glucose exchange disorders in patients taking glucocorticosteroids: features of clinical manifestations and correction. Kubanskiy nauchnyy meditsinskiy vestnik = Kuban Scientific Medical Bulletin 2019;26(1):209–18. (In Russ.). DOI: 10.25207/1608-6228-2019-26-1-209-218Селимов А.Ю., Елисеева Л.Н., Куринная В.П., Оранский С.П. Нарушения обмена глюкозы у пациентов, принимающих глюкокортикостероиды: особенности клинических проявлений и коррекции. Кубанский научный медицинский вестник 2019;26(1):209–18. DOI: 10.25207/1608-6228-2019-26-1-209-218Agudo-Tabuenca A., Gimeno-Orna J.A., Sáenz-Abad D. Assessment of the efficacy and safety of a protocol to manage glucocorticoid-induced hyperglycemia in diabetic patients during hospital stay. Endocrinol Diabetes Nutr 2019;66(6):353–60. DOI: 10.1016/j.endinu.2019.01.008Wallace M.D., Metzger N.L. Optimizing the treatment of steroid-induced hyperglycemia. Annal Pharmacother 2018;52(1):86–90. DOI: 10.1177/1060028017728297Vu K., Busaidy N., Cabanillas M.E. et al. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2012;12(5):355–62. DOI: 10.1016/j.clml.2012.05.004Beaupere C., Liboz A., Fève B. et al. Molecular mechanisms of glucocorticoid-induced insulin resistance. Int J Mol Sci 2021;22(2):623. DOI: 10.3390/ijms22020623Welsch S., Sawadogo K., Brichard B. et al. Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies. Diabet Med 2022;39(2):e14720. DOI: 10.1111/dme.14720Suh S., Park M.K. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab 2017;32(2):180–9. DOI: 10.3803/EnM.2017.32.2.180Bonaventura A., Montecucco F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract 2018;139:203–20. DOI: 10.1016/j.diabres.2018.03.006Gebauer J., Fick E.M., Waldmann A. et al. Self-reported endocrine late effects in adults treated for brain tumours, Hodgkin and non-Hodgkin lymphoma: a registry based study in Northern Germany. Eur J Endocrnol 2015;173(2):139–48. DOI: 10.1530/eje-15-0174Hirabayashi K., Nakazawa Y., Matsuura H. et al. Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies. Int J Hematol 2014;99(4):477–86. DOI: 10.1007/s12185-014-1536-8Li C., Liu P., Liu L. et al. Metabolic syndrome in hematologic malignancies survivors: a meta-analysis. Med Oncol 2015;32(1):422. DOI: 10.1007/s12032-014-0422-9Šimkovič M., Vodárek P., Motyčková M. et al. Rituximab, cyclophosphamide and dexamethasone (RCD) chemoimmunotherapy for relapsed chronic lymphocytic leukaemia. Eur J Clin Invest 2020;51(4):e13421. DOI: 10.1111/eci.13421Ceccarelli E., Mattaliano C., Brazzi A. et al. Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations. Curr Pharm Biotechnol 2018;19(15):1210–20. DOI: 10.2174/1389201020666190102145305Cavataio M.M., Packer C.D. Steroid-induced diabetic ketoacidosis: a case report and review of the literature. Cureus 2022;14(4):e24372. DOI: 10.7759/cureus.24372Jung S.H., Jang H.C., Lee S.S. et al. The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. Biomed Res Int 2014;2014:413149. DOI: 10.1155/2014/413149Weiser M.A., Cabanillas M.E., Konopleva M. et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004;100(6):1179–85. DOI: 10.1002/cncr.20071Gonzalez-Gonzalez J.G., Mireles-Zavala L.G., Rodriguez-Gutierrez R. et al. Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients. Diabetol Metab Syndr 2013;5:18. DOI: 10.1186/1758-5996-5-18Lee S.Y., Kurita N., Yokoyama Y. et al. Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Support Care Cancer 2014;22(5):1385–90. DOI: 10.1007/s00520-013-2097-8Bostrom B.C., Sensel M.R., Sather H.N. et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 2003;101(10):3809–17. DOI: 10.1182/blood-2002-08-2454Teuffel O., Kuster S.P., Hunger S.P. et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011;25(8):1232–8. DOI: 10.1038/leu.2011.84Bielorai B., Pinhas-Hamiel O. Type 2 diabetes mellitus, the metabolic syndrome, and its components in adult survivors of acute lymphoblastic leukemia and hematopoietic stem cell transplantations. Curr Diab Rep 2018;18(6):32. DOI: 10.1007/s11892-018-0998-0Lamar Z.S., Dothard A., Kennedy L. et al. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration – a retrospective study. Leuk Lymphoma 2018;59(8):1871–7. DOI: 10.1080/10428194.2017.1410889Pagano G., Cavallo-Perin P., Cassader M. et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983;72(5): 1814–20. DOI: 10.1172/JCI111141Weinstein S.P., Wilson C.M., Pritsker A., Cushman S.W. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998;47(1): 3–6. DOI: 10.1016/s0026-0495(98)90184-6Seckl J.R., Morton N.M., Chapman K.E., Walker B.R. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004;59:359–93. DOI: 10.1210/rp.59.1.359Linssen M.M., van Raalte D.H., Toonen E.J. et al. Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. Cell Signal 2011;23(11):1708–15. DOI: 10.1016/j.cellsig.2011.06.002Esguerra J.L.S., Ofori J.K., Nagao M. et al. Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA. Mol Metab 2020;32:160–7. DOI: 10.1016/j.molmet.2019.12.012Roberts A., James J., Dhatariya K. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabetic Med 2018;35(8):1011–7. DOI: 10.1111/dme.13675Dev R., Bruera E., Dalal S. Insulin resistance and body composition in cancer patients. Ann Oncol 2018;29(suppl_2):ii18–26. DOI: 10.1093/annonc/mdx815Tanaka K., Okada Y., Mori H. et al. The effects of mitiglinide and repaglinide on postprandial hyperglycemia in patients undergoing methylprednisolone pulse therapy. Intern Med 2018;57(1):65–70. DOI: 10.2169/internalmedicine.9013-17Boren J., Cascante M., Marin S. et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 2001;276(41):37747–53. DOI: 10.1074/jbc.M105796200Clore J.N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15(5):469–74. DOI: 10.4158/EP08331.RARPerez A., Jansen-Chaparro S., Saigi I. et al. Glucocorticoid-induced hyperglycemia. J Diabetes 2014;6(1):9–20. DOI: 10.1111/1753-0407.12090Zarkovic M., Beleslin B., Ciric J. et al. Glucocorticoid effect on insulin sensitivity: a time frame. J Endocrinol Invest 2008;31(3):238–42. DOI: 10.1007/BF03345596Gounden V., Ngu M., Anastasopoulou C., Jialal I. Fructosamine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022.Olczuk D., Priefer R. A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus. Diabetes Metab Syndr 2018;12(2):181–7. DOI: 10.1016/j.dsx.2017.09.005Fonseca V.A., Grunberger G., Anhalt H. et al. Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract 2016;22(8):1008–21. DOI: 10.4158/EP161392.CSSeelig E., Meyer S., Timper K. et al. Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol 2017;176(3):349–58. DOI: 10.1530/EJE-16-0653Willi S.M., Kennedy A., Brant B.P. et al. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract 2002;58(2):87–96. DOI: 10.1016/s0168-8227(02)00127-4Wu W., Merriman K., Nabaah A. et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 2014;111(3):628–36. DOI: 10.1038/bjc.2014.307De Micheli A. [Corticosteroid induced diabetes mellitus: diagnosis and management] (In Italian). G Ital Nefrol 2016;33(S68):gin/33.S68.7.Ali N.A., O’Brien J.M.Jr, Blum W. et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer 2007;110(1):96–102. DOI: 10.1002/cncr.22777Kuvshinov A.Yu., Voloshin S.V., Kuzyaeva A.A. et al. Current views on CAR-Т therapy. Vestnik gematologii = Bulletin of Hematology 2019;15(2):4–13. (In Russ.).Кувшинов А.Ю., Волошин С.В., Кузяева А.А. и др. Современные представления о CAR-T-клеточной терапии. Вестник гематологии 2019;15(2):4–13.